NASDAQ:HRTS Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) Price, Holdings, & News $28.27 +0.12 (+0.43%) As of 06/18/2025 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock About Tema GLP-1, Obesity & Cardiometabolic ETF (NASDAQ:HRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HRTS alerts:Sign Up Key Stats Today's Range$28.09▼$28.3350-Day Range$26.75▼$29.2052-Week Range$25.32▼$36.03Volume2,191 shsAverage Volume9,873 shsMarket Capitalization$53.71 millionAssets Under Management$50.27 millionDividend Yield1.63%Net Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.Read More… Tema GLP-1, Obesity & Cardiometabolic ETF ExpensesTypeHRTSNASDAQ ETFsAll ETFsManagement Fee0.99%0.54%0.53%Other Expenses0.00%0.52%0.56%Total Expense0.99%0.74%0.73%Fee Waiver-0.24%-0.50%-0.63%Net Expense0.75%0.63%0.60% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema GLP-1, Obesity & Cardiometabolic ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTS ETF News HeadlinesWeight-Loss Drug ETFs Generate Skinnier Returns Than ExpectedJune 11, 2025 | finance.yahoo.comHRT may help to protect the heartOctober 22, 2024 | dailymail.co.ukNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.June 19, 2025 | American Alternative (Ad)Investing in Real Assets: The Growing Demand and Opportunity with Brompton’s BREA ETFOctober 10, 2024 | theglobeandmail.comOil Prices Spike Amid Middle East TensionsOctober 8, 2024 | theglobeandmail.comGuardian Capital LP Launches Two New ETFs on CBOE CanadaOctober 8, 2024 | theglobeandmail.comSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema GLP-1, Obesity & Cardiometabolic ETF's stock was trading at $28.87 at the start of the year. Since then, HRTS shares have decreased by 2.1% and is now trading at $28.27. View the best growth stocks for 2025 here. Who are Tema GLP-1, Obesity & Cardiometabolic ETF's major shareholders? Tema GLP-1, Obesity & Cardiometabolic ETF's top institutional shareholders include Sterling Investment Advisors Ltd. (9.40%) and Flow Traders U.S. LLC (2.97%). How do I buy shares of Tema GLP-1, Obesity & Cardiometabolic ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tema GLP-1, Obesity & Cardiometabolic ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema GLP-1, Obesity & Cardiometabolic ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Fund Details IssuerTema Global Fund NameTema GLP-1, Obesity & Cardiometabolic ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset Class BenchmarkN/A Category Focus Development Level Region Number of Holdings47 Fund Statistics Assets Under Management$50.27 million Average Daily Volume$0.00 Discount/Premium-0.09% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerN/A Options OptionableN/A Short Interest400 shs Miscellaneous Outstanding Shares1,900,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Top 10 HRTS HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 9.71%Novo Nordisk A/SHolding Weight: 4.92%Abbott Laboratories (NYSE:ABT)Holding Weight: 4.41%AstraZeneca PLCHolding Weight: 4.14%Roche (OTCMKTS:RHHBY)Holding Weight: 4.06%UnitedHealth Group (NYSE:UNH)Holding Weight: 3.61%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.39%US DOLLARSHolding Weight: 3.19%Boston Scientific (NYSE:BSX)Holding Weight: 3.17%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.11%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema GLP-1, Obesity & Cardiometabolic ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema GLP-1, Obesity & Cardiometabolic ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTS Stock Free HRTS Stock Alerts